Palmitoylethanolamide (Pea) for Anti-Inflammatory

Research suggests that palmitoylethanolamide (PEA) has meaningful anti-inflammatory properties, with the available evidence spanning multiple review articles, preclinical animal studies, laboratory studies in human tissue, and at least one small pilot randomized controlled trial — the majority of which point in a supportive direction. Studies indicate that PEA works through several molecular pathways, most notably by activating a receptor called PPAR-α, which in turn suppresses major drivers of inflammation such as NF-κB signaling, and preclinical work has demonstrated anti-inflammatory effects in models relevant to conditions ranging from colitis and uveitis to sepsis and sickle cell disease. Laboratory research also suggests that preserving the body's own PEA levels — by blocking the enzymes that break it down — may amplify these effects, and one small human study found measurable increases in plasma PEA following oral supplementation alongside reductions in inflammation markers in immune cells. However, the evidence base is still heavily weighted toward animal models and cell studies, human clinical trial data remains limited, and researchers have noted that historical challenges with oral absorption, though partially addressed by newer formulation technologies, represent an ongoing consideration when interpreting findings.